New PAREXEL division supports emerging biotech companies

08-Jan-2019 - PAREXEL International Corporation introduced a new, dedicated division to support emerging biotech companies in reaching their drug development and commercialization goals quickly and cost-effectively. PAREXEL Biotech builds on the Company’s heritage of clinical, regulatory, commercial and ...

PAREXEL appoints Jamie Macdonald as Chief Executive Officer

Company Co-founder Josef von Rickenbach to retire after 35 years

08-Mar-2018 - PAREXEL International Corporation announced the appointment of Jamie Macdonald as Chief Executive Officer (CEO) effective March 15, 2018. Josef von Rickenbach, who co-founded the Company, will retire from his daily CEO duties and continue as Chairman of the Board. “It is a tremendous honor for me ...

PAREXEL announces agreement to acquire The Medical Affairs Company

03-Feb-2017 - PAREXEL International Corporation, a biopharmaceutical services provider, announced that the Company has entered into a definitive agreement to acquire The Medical Affairs Company, a provider of outsourced medical affairs services to the pharmaceutical, biotechnology, and medical device ...

Parexel launches expanded genomic research services

18-Feb-2016 - Parexel International Corporation announced expanded services and capabilities in genomic-based drug development. The PAREXEL®Genomic Medicine team offers clients a variety of strategic and operational genomic research services to accelerate drug development and to support regulatory and payer ...

PAREXEL International Announces Acquisition Of ATLAS Medical Services

04-Jul-2014 - PAREXEL International Corporation announced that the Company has acquired all of the outstanding equity securities of ATLAS Medical Services, a provider of clinical research services in Turkey, the Middle East, and North Africa.ATLAS provides services across all phases of clinical development and ...

Parexel Names Dr. Sy Pretorius Chief Scientific Officer

30-May-2014 - Parexel International named Dr. Sy Pretorius its Chief Scientific Officer. Dr. Pretorius currently serves as the Company’s Corporate Vice President and Worldwide Head of Early Phase, and will continue in that capacity in addition to assuming his expanded responsibilities. As Chief Scientific ...

UCB enters into strategic partnerships in clinical development with PAREXEL and PRA

Strategic partnerships for focused global operational clinical development activities, using complementary strengths and expertise

17-Nov-2011 - UCB announced that it has entered into strategic partnerships with PAREXEL and PRA to drive UCB’s operational clinical development activities. The agreements are effective for all of UCB’s new clinical study programs on a global basis."We are pleased to announce these strategic partnerships as ...

Revotar AG starts supplementary clinical phase-I study with bimosiamose

01-Nov-2005 - Revotar Biopharmaceuticals AG announced that it has started a phase-I study with its drug bimosiamose, a pan-selectin antagonist. In this double-blind, placebo-controlled, randomized trial, safety and tolerability as well as pharmacokinetic characteristics of subcutaneously administered single ...

PAREXEL Forms Collaboration With Clinical Research Services Provider in India

29-Apr-2004 - PAREXEL International Corporation announced that it has entered into an exclusive strategic collaboration with Synchron Research Services Private Limited, a privately held contract research organization headquartered in Ahmedabad, India. Founded in 1998, Synchron provides a broad range of Phase ...